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ABSTRACT
Objective: To determine the clinical efficacy of laser ablation for the tredatment of primary hyperpara-
thyroidism (pHPT).
Materials and methods: Twelve patients with pHPT were treated with laser ablation. Energy was
administered by means of 1.5m optical fibers percutaneously placed into the target via 21G needles.
A laser ablation unit (EchoLaser X4, Esaote) applied 3W power for 400–600 s/fiber/insertion to a total
3600–9000 Joules of energy. Patient serum parathyroid hormone (PTH) and calcium levels were
checked at baseline and thereafter every 6 months. Patients were followed-up for 2 years with sero-
logic and contrast-enhanced ultrasound. Therapeutic success was defined as normal PTH and calcium
levels together with disappearance of nodule-related symptoms.
Results: All procedures were performed in single session. Immediately following ablation, contrast
enhanced ultrasound confirmed that all but one target had become avascular (technical success rate
11/12; 92%), remaining avascular at all follow-up ultrasound examinations, thereafter. The mean vol-
ume of parathyroid nodules decreased from 0.54 cc to 0.36 cc (72.0%). Serum PTH and calcium levels
were significantly lower at 1, 12 and 24m compared to baseline (p< 0.01). By 6m, PTH and calcium
returned to normal and were stable until 24m in all successfully treated patients. All cases of hyper-
parathyroid-related symptoms resolved by 6m (ostealgia [n¼ 5], repeated renal colic [n¼ 5], vomiting
[n¼ 3]). Only one patient (8%) reported transient dysphonia as a minor complication.
Conclusion: Laser ablation of enlarged, symptomatic parathyroid glands is safe and well-tolerated and
can produce long-term, sustained reduction of serum PTH and calcium levels.
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Introduction
Primary hyperparathyroidism (pHPT) is the most common
cause of chronic hypercalcemia, with its incidence increasing
with age [1]. Single-gland adenoma is the most common
cause (75–85%), and in most patients, it can be clearly identi-
fied by ultrasound [2]. Surgery is the recommended treat-
ment for patients with symptomatic pHPT due to its high
long-term cure rate. However, potentially both radical neck
exploration and associated procedural general anesthesia can
be associated with morbidity. This is even further increased
in elderly patients and/or patients with comorbidities that
are contraindications to surgery under general anesthesia
[1,3–5]. Furthermore, pHPT patients with few or no symp-
toms, most often detected during screening programs, may
decline surgery. For these reasons, it is often difficult to
advise individual patients about the correct balance between
long-term advantages and disadvantages of surgery. This
explains the considerable interest in identifying therapeutic
alternatives to surgery for pHPT.
Initially, minimally invasive image-guided therapy for
pHPT was performed with chemical ablation, using ethanol
as the sclerosing agent [6,7]. However, over time this
approach aroused progressively reduced enthusiasm, particu-
larly as the success rate of percutaneous ethanol instillation
was found to be inversely correlated with the size of the
parathyroid tumor and duration of follow-up [8–13].
Moreover, side effects were not uncommon, and included
pain, vocal cord affection and extra-parathyroid fibrosis,
which could hamper subsequent surgery [10], if needed.
Some of these issues have been directly attributed to poor
control of the diffusion of the chemical agent. Thus, the use
of thermal ablation sources could potentially overcome these
challenges – if adequate precision and safety could be
achieved. One potential solution is the use of laser ablation
whose energy distribution pattern may be more focal and
controlled than radiofrequency (RF) or microwave ablation
(MW) [14–17]. Specifically, light energy has a potential advan-
tage in that it may be delivered interstitially by implanting
extremely thin lasers fiber directly into body tissues under
real-time imaging guidance, potentially further reducing
issues of cosmesis that may accompany larger applicator
sizes [17]. Laser thermal ablation has been applied experi-
mentally and clinically [14–17] for palliative therapy in a var-
iety of primary and secondary malignant neoplasms and also
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for the ablation of benign lesions. Thus, the aim of the pre-
sent study was to evaluate the feasibility, safety and efficacy
of laser ablation for the treatment of pHPT in patients who
were ineligible for surgery or refused surgery.
Materials and methods
This retrospective study was approved by our local ethical
committee, and all patients signed informed consent prior to
each procedure.
Study cohort
From 3/2011 to 3/2014, a total of 12 patients (three men
and nine women; mean age 67 y± 8.2; age range, 43–81 y)
were treated with US-guided laser ablation in our depart-
ment. All patients had a single target nodule located in one
side of the neck. Patients were enrolled if they fulfilled the
following criteria: age 18 years, diagnosis of hyperparathyr-
oidism on the basis of recommendations proposed by the
International Workshop on pHPT, i.e., lesion diameter
30mm, lack of suitability or willingness to undergo surgery
and follow-up for at least 2 years after ablation [7]. The base-
line size of the parathyroid nodules (largest diameter meas-
ured at ultrasound), and patient demographic details,
baseline serum parathyroid hormone (PTH) and calcium lev-
els are summarized in Table 1. All had classic sonographic
features of a hypervascular, hypoechoic, capsulated solid
nodule, in 8/12 (66.7%) cases lying in close proximity with
the laryngeal recurrent nerve.
Imaging and ablation equipment
The ablation unit (EchoLaser X4, Esaote, Genova, Italy) used
combines both an ultrasound scanner and a 4–13MHz linear
transducer with a laser system. This system has four inde-
pendent laser channels and is based upon a Diode laser of
1064 nm wavelength that produces a beam with diameter of
0.3mm and an output power level ranging from 1 to 7W.
Optical fibers of 1.5m with a 300 mm core can be percutan-
eously placed into the target via 21G needles. A needle
guide with different angles enables one or two simultaneous
insertions. Three watts power was applied for 400–600 s/
fiber/insertion with 1600–7200 Joules total energy applied.
A pull-back technique was employed by treating the deepest
portion of the nodule until hyperechogenicity surrounded
the fiber at which point the fiber was manually retracted to
enable treatment of more superficial portions of the lesion
[17]. The system has a touch screen laser display, allowing to
independently select the energy delivered by each fiber. The
procedure was technically facilitated by the use of dedicated
software enabling to precisely plan the location of needle
insertion and to predict final ablation volume (Elesta
Echolaser, Calenzano, FI, Italy).
In all patients, contrast-enhanced ultrasound (CEUS) was
performed immediately before and 5–7min after the end of
ablation. A single dose of 4.8ml of sulfur hexafluoride micro-
bubbles (SonoVue, Bracco, Italy) was intravenously adminis-
tered both before and after ablation to monitor and assess
the therapeutic result before terminating the ablation ses-
sion. Contrast-specific software (Contrast-tuned Imaging –
CnTI, Esaote, Italy) in continuous mode, with very low mech-
anical index (0.01–0.1) was employed. The aim of CEUS was
to demonstrate the complete post-ablation avascularity of all
the parathyroid adenomas, in comparison with their pre-
ablation diffuse hypervascularity (mostly in arterial phase).
Procedure
All treatments were performed as outpatient procedures by
a team of two experienced radiologists working in tandem,
each have been performing ultrasound-guided biopsies and
ablations for clinical care for over 10 and 25 years, respect-
ively. Patients were placed in a supine position with their
neck extended. Local anesthesia was achieved by subcutane-
ous (up to the anterior surface of the parathyroid adenoma)
injection of 1–2ml of 2% lidocaine (AstraZeneca, Basiglio, MI,
Italy) and 3ml of Ropivacaine (Aspen Pharma, Dublin,
Ireland). Next, the needle insertion path and the ablation vol-
ume to be achieved was planned using the dedicated plan-
ning software system. The adenoma was then targeted
under direct ultrasound guidance along its longest axis,
using either one or two simultaneous insertions (Figures 1
and 2). Once adequate positioning of the fiber was ascer-
tained by ultrasound, laser energy was delivered and con-
trolled independently for each fiber. Pull-back of the fibers
commenced once the echogenicity reached the margin of
the gland. The fiber tip was initially positioned in the
Table 1. patient demographic and laboratory details.
Age Sex
Parathyroid
maximum
diameter (cm)
Location in
relation
to thyroid Clinical symptoms
Pretreatment
calcium levels
(mg/dL)
Pretreatment PTH
levels (pg/mL)
1 43 F 1 Caudal Repeat renal colic 10.5 259
2 71 F 1.3 Retrothyroidal Bone pain, renal stones 11 92
3 85 F 3 Caudal Renal colic, nausea and vomiting 13.3 900
4 65 F 2 Caudal Increasing bone pain and arthralgia 11.8 371
5 69 F 1.3 Caudal Severe osteoporosis 12.1 367
6 69 F 1.6 Retrothyroidal Nephrolithiasis, severe osteoporosis 9.9 151
7 53 F 1.2 Caudal Repeated renal colic, nausea and vomiting 10.3 128
8 81 M 1.3 Retrothyroidal Severe arthralgia and increasing bone pain 11.3 290
9 78 F 1.1 Retrothyroidal Nephrocalcinosis 11.4 127
10 41 M 1.7 Caudal Severe bone pain, repeat renal colic 13.8 2000
11 75 F 0.9 Caudal Bone pain and arthralgias 11.5 150
12 67 M 1.6 Caudal Renal colic, vomiting 10.1 160
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deepest portion of the nodule, and once an echogenic spot
of approximately 10-mm diameter and length surrounded it,
the fiber was gradually withdrawn in millimeter increments
more proximally toward the superficial untreated portion of
the tumor. Throughout the entire procedure, the patients
were intermittently interrogated, with the intent of assessing
their status of phonation. Upon completing the treatment,
we attempted to minimize bleeding complications with light
compression on the neck for 15min and subsequently eval-
uated for any complications while keeping patients under
direct observation for 2–4 h. Patients were discharged if there
was no complication that required hospitalization.
Pre-ablation assessment
All patients were evaluated by ultrasound examination, 99mTc
sestamibi scintigraphy, laboratory examinations and clinical
symptoms assessment. The ultrasound assessment included
size, location and volume documentation (V¼ 0.5 
height depthwidth). Laboratory examinations included
measurements of serum PTH (normal range, 20–80pg/mL,
Intact PTH (Beckman Coulter S.p.A., Cassina de’ Pecchi, Milan,
Italy), and serum Calcium, (Arsenazo- Beckman Coulter S.p.A.,
Cassina de’ Pecchi, Milan, Italy, normal ranges from 8.6
to 10.3mg/dl), in addition to platelet count and blood coagu-
lation tests. Given that a large portion (up to 45%) of serum
calcium bound to proteins, mainly albumin, in all our patients
the reported serum calcium was corrected for albumin using
the following calculation: corrected calcium¼measured cal-
cium (mg/dl) þ 0.8 [4 – serum Albumin (g/dl)].
Follow-up evaluation
All patients underwent a medical visit, ultrasound and blood
tests for serum PTH and calcium measurements prior to the
procedure, and at 1, 6, 12 and 24months after the procedure.
Figure 1. Single-fiber laser ablation for primary hyperparathyroidism. (A) A 69-year-old female presented with severe osteoporosis, nephrocalcinosis and elevated
parathormone levels. A 1.6 0.6 cm adenoma was identified behind the lower pole of the thyroid. (B) Contrast enhanced ultrasound confirms marked homoge-
neous vascularity. (C) Gray scale ultrasonography demonstrates insertion of a single fiber (central white line) along the longitudinal axis of the gland. Normalization
of parathormone was noted at 6months. (D) Two-year follow-up shows a marked reduction in the gland size (0.7 0.4 cm) with elimination of vascularity at con-
trast enhanced ultrasound (yellow circle).
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During these visits, potential nodule-related symptoms such as
bone pain and renal colic, and/or other complications (hemato-
mas, skin burns, fever, voice change, brachial plexus injury and
Horner syndrome) were recorded. Therapeutic success was
defined by normal PTH and calcium levels at 24-month follow-
up together with disappearance of nodule-related symptoms.
Statistical analysis
Values for quantitative variables are expressed as means ±
standard deviation and range. Wilcoxon signed-rank tests
were used to compare changes in largest nodule diameter,
volume, vascularity and serum PTH and calcium levels from
Figure 2. Dual-fiber laser ablation for primary hyperparathyroidism. (A) A 65-year-old female presented with increasing bone pain and arthralgia, increased para-
thormone levels and hypercalcemia. A 2.0 1.3 cm adenoma was identified at gray scale ultrasound caudal to the thyroid. (B) Contrast enhanced ultrasound dem-
onstrated a heterogeneously enhancing nodule. (C) Baseline Tc-99 Sestamibi is highly positive (red color). (D) Intraprocedural gray scale ultrasound demonstrated
the placement of two laser fibers spaced 1 cm apart inserted into the gland. (E) Increased echogenicity is identified surrounding the fibers during the active applica-
tion of laser energy. Normalization of parathormone and calcium levels occurred by 6months. (F) Two-year follow-up gray scale and contrast enhanced ultrasound
demonstrate a non-enhancing 0.9 0.7 cm gland. (G) Tc-99 Sestamibi shows no evidence for increased uptake.
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before ablation to follow-up. Differences were considered
statistically significant when the p value was less than 0.05.
All analyses were conducted using SPSS for Windows (ver-
sion16.0; IBM, Armonk, New York).
Results
All procedures were performed in a single session and all
except one were successful (technical success rate of 11/
12¼ 92%). Three patients (25%) had two fibers activated,
with the remainder of the procedures performed using a sin-
gle fiber. The single refractory patient had an exceptionally
high PTH level (2000) that did not decrease significantly
post-ablation, and thus, after the 6-month follow-up he was
referred to surgical parathyroidectomy. The pathological spe-
cimen clearly documented a central focus of ablated tissue
in the center of this gland. All treatments were performed
administering 3W power for a duration ranging from 400 to
600 s/fiber/insertion. The mean total amount of energy deliv-
ered was 3533 ± 1893 Joules. The mean duration of the
energy delivery was 10.2min ± 1.2 (range 8.0–14min).
Treatment response and clinical outcome
Characteristics of the parathyroid nodules were measured
before laser ablation and at each follow-up period. Largest
diameter, volume and vascularity of the nodules were signifi-
cantly lower at last follow-up than before treatment. The
largest diameter decreased from 3.0 to 2.1 cm. The mean vol-
ume of parathyroid nodules decreased from 0.54 to 0.36 cc
(72.0 ± 15.9%). Following ablation, contrast enhanced ultra-
sound confirmed that all targets had become avascular, and
with the exception of the single case of recurrence remained
avascular at all follow-up ultrasound examinations.
The changes in serum PTH and calcium levels before abla-
tion and at each follow-up period are summarized in Table
2. Serum PTH and calcium levels were significantly lower at
1, 12 and 24months compared to before treatment (p< 0.01
for all comparisons), with stable reductions seen when com-
paring 12 to 24m (p> 0.50). In 11/12 (91.7%) patients, PTH
and calcium levels returned to normal, and 99mTc sestamibi
scintigraphy confirmed success of the ablation (Figures 1 and
2). These, together with disappearance of nodule-related
symptoms including ostealgia (in all five cases where
present), and vomiting (three patients) by 6 months post-
ablation revealed the effectiveness of ablation. Likewise,
none of the five patients with repeated bouts of renal colic
reported further episodes over the 2-year follow-up.
Side effects and complications
The treatment was well tolerated. A mild sensation of heat in
the neck was experienced by most patients, but no patient
requested termination of the procedure. Only one patient
(8.3%) reported a transient voice change, and laryngoscopic
evaluation demonstrated vocal-cord palsy, but this resolved
without any treatment within 3weeks. No cases of local
infection, skin burning or damage to the vital structures
were observed.
Discussion
Surgical parathyroidectomy is the gold-standard treatment
for pHPT. However, not all patients are ideal candidates or
even eligible for surgery. Thus, early interventional oncolo-
gists proposed US-guided percutaneous ethanol injection to
parathyroid adenomas and proved its utility in treating pHPT
in highly selected patients [6,7]. Nevertheless, because of
the need for repeated ethanol injections, based in part upon
the significant incidence of relapse, and reported side effects,
the use of percutaneous ethanol injection for pHPT is less
than ideal [8–13]. Accordingly, in a manner similar to the
ultimate migration from chemical ablation to thermal based
methods for the treatment of hepatocellular carcinoma [18],
RF and microwave have been proposed as possible ablation
techniques for PTA ablation. Thus, several series such as by
Liu et al. [19], have shown MW ablation to be feasible.
However, the very high temperatures of microwave have
raised a substantial concern of safety, particularly issues of
overtreatment leading to damage of adjacent structures by
high energy sources [20].
US-guided laser ablation has been proposed as a poten-
tially better match for PTA ablation. Prior reports have noted
extremely well-defined, well-demarcated zones of ablation,
based upon limited energy penetration. Thus, although these
attributes of laser ablation may not be ideal for the treat-
ment of liver metastases and have led to greater adoption of
other energy sources in the liver [21–24], these very proper-
ties are likely to be more suited for parathyroid pathology.
Several series of US-guided laser ablation for parathyroid
adenomas have been published, all based either upon few
patients or short post treatment follow-up period. Andrioli
et al. [16], published a series of six patients, with a mean
duration of follow-up of 54± 34months. Laser ablation ther-
apy was safe and without permanent side effects. Similar to
our series, one patient reported transient dysphonia. Two
months after laser ablation, serum PTH and calcium levels
decreased in six and five patients, respectively. At the last
follow-up examination, serum PTH and calcium levels were
Table 2. The changes in serum PTH and albumin- corrected calcium levels before ablation and at each follow-up period.
Baseline 1Mo 6Mo 12Mo 24Mo
Volume (cm3) 0.54 ± 0.47 0.46 ± 0.42 0.36 ± 0.36 0.36 ± 0.38 0.36 ± 0.34
PTH (pg/mL)
(20 to 80 pg/mL)
416 ± 230 357 ± 526 58 ± 19 52 ± 17 60.5 ± 25
Calcium (mg/dL)
(8.6–10.3mg/dl)
11.4 ± 1.2 10.6 ± 1.4 9.6 ± 0.7 9.5 ± 0.6 9.3 ± 0.7
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above the normal range in six and three patients, respect-
ively. Nevertheless, three patients (i.e., half the population)
underwent surgery for persistent pHPT. Overall, they con-
cluded that laser ablation produces a transient reduction of
serum PTH and calcium levels but not a lasting resolution of
hyperparathyroidism. On the other hand, Jiang et al. [25],
treated 21 patients, with only 1-year follow-up. They used
contrast-enhanced sonography guidance for the procedure.
Normalization of PTH and serum calcium was achieved in
81% of the patients at 1 year follow-up. No serious complica-
tions were observed. They concluded that ultrasound-guided
PTA laser ablation with CEUS is a viable alternative to surgery
for primary parathyroid adenoma.
In our study, we report upon 12 patients with a full 2-
year follow-up. All procedures were performed in a single
session and all except one were successful (technical success
rate of 11/12¼ 92%). This single refractory patient had an
exceptionally high PTH level that did not decrease signifi-
cantly post-ablation, and thus, after the 6-month follow-up
he was referred to surgical treatment. The treatment was
well tolerated by all patients. Vocal-cord palsy in one patient
resolved without any treatment within 3weeks. On the other
hand, resolution of the clinical symptoms of bone pain and
repeat renal colic associated with hyperparathyroidism were
noted in all 10 patients where present by 6-months fol-
low-up.
Interestingly, for the majority of patients (and all success-
fully treated patients) we noted a slow, but progressive
return to normal serological levels. Trends to normalization
of calcium and PTH were seen at 1m, but only truly normal
values were achieved at 6months. Most notably these
remained stable and within the normal range in all cases by
the 2-year follow-up.
Although we demonstrate excellent 2 years outcomes
including resolution of the major clinical symptoms and com-
plaints in the majority of our patients, it must be noted that
several earlier series reported only transient reduction of
serum PTH and calcium levels, with recurrence of hyperpara-
thyroidism, for example the study by Andrioli mentioned ear-
lier [16]. Analysis of these suggest that their population had
much greater and/or aggressive disease. Indeed, we note the
relatively small volumes of the parathyroid glands in our
study. Accordingly, similar to most other ablation procedures,
judicious patient selection is likely critical for ensuring opti-
mal results, and further study is needed to better define and
categorize the different patient sub-populations.
Alternatively, differences in technique may be responsible for
the differences in results achieved. For example, it is well-
known that parathyroid cells have the capacity to grow and
replicate [26,27]. Persistence of even a few adenomatous
parathyroid cells after ablation might result in suboptimal
efficacy of ablation and require more treatment sessions.
Therefore, complete ablation of the periphery of the parathy-
roid nodule is important to prevent marginal regrowth.
Indeed, we note greater amounts of energy per target vol-
ume deposited in our study compared to previous ser-
ies [16].
Overall, we found that laser ablation creates a sharp
demarcation line between the treated-necrotic tissue, and
the untreated surrounding structures [26]. We further note
that contrast enhanced ultrasound enables to clearly depict
this demarcation line and to add ablation session if neces-
sary. This ensures complete ablation with minimal surround-
ing damage and minimizes the risk of recurrence. Moreover,
one potential benefit of laser is the ability to split the energy
delivery via multiple fibers in an array [28]. Likewise, we note
that the thin pliant laser fibers were extremely easy to use.
Given that they are less cumbersome than larger MW and RF
probes, they may cause less damage and hence hold the
potential for better cosmesis than other methods of ther-
mal ablation.
Clearly, our work is subject to many of the same limita-
tions facing many retrospective reports of interventional
oncologic procedures performed for relatively rare disease
states or conditions. Specifically, we note the limited number
of patients and limited follow-up interval. Indeed, we
acknowledge that additional recruitment and further study
may enable us to gain further insights such as whether or
not we can identify which patients present with findings that
make therapy unlikely to be successful. A case in point is the
unsuccessful treatment of our patient with the highest PTH
level. This suggests that there may be a predictive cutoff
above which the disease is too aggressive to realistically
anticipate success. Yet, a single case is clearly insufficient to
draw definitive conclusions on this issue.
Conclusion
Our results using laser ablation to treat patients with func-
tional parathyroid adenomas demonstrate high levels of sus-
tained complete response at the clinically relevant follow-up
period of 24months compared. Hyperparathyroid clinical
symptoms disappeared by 6months and sustained serologic
normalization of parathormone and calcium were seen by
6months as well. Although these findings support the use of
laser ablation as an effective minimally invasive therapy for
primary hyperthyroidism, future work including larger series
with more patients and longer follow-up periods is likely
warranted. Defining the true range of optimal patients and
the upper limit in size and number for a single or multiple
fiber approach should be further investigated as well.
Medical relevance
Our results using laser ablation to treat patients with func-
tional parathyroid adenomas demonstrate high levels of sus-
tained complete response at the clinically relevant follow-up
period of 24months compared.
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